Your browser is no longer supported. Please, upgrade your browser.
SIGA SIGA Technologies, Inc. daily Stock Chart
SIGA Technologies, Inc.
Index- P/E- EPS (ttm)-0.53 Insider Own2.40% Shs Outstand79.62M Perf Week4.93%
Market Cap575.65M Forward P/E- EPS next Y- Insider Trans- Shs Float52.37M Perf Month-11.51%
Income-41.50M PEG- EPS next Q- Inst Own25.40% Short Float2.65% Perf Quarter4.78%
Sales7.20M P/S79.95 EPS this Y28.90% Inst Trans18.59% Short Ratio4.15 Perf Half Y18.91%
Book/sh-4.32 P/B- EPS next Y- ROA-27.90% Target Price11.00 Perf Year133.98%
Cash/sh0.13 P/C54.31 EPS next 5Y1.00% ROE11.80% 52W Range2.90 - 8.47 Perf YTD49.07%
Dividend- P/FCF- EPS past 5Y-12.60% ROI7.70% 52W High-14.64% Beta0.62
Dividend %- Quick Ratio0.30 Sales past 5Y6.50% Gross Margin- 52W Low149.31% ATR0.34
Employees37 Current Ratio0.30 Sales Q/Q-37.20% Oper. Margin- RSI (14)46.38 Volatility4.63% 4.52%
OptionableYes Debt/Eq- EPS Q/Q6.30% Profit Margin- Rel Volume1.22 Prev Close6.75
ShortableYes LT Debt/Eq- EarningsSep 28 AMC Payout- Avg Volume334.07K Price7.23
Recom- SMA20-3.98% SMA50-3.77% SMA20015.07% Volume408,852 Change7.11%
Sep-17-18 07:30AM  SIGA Technologies to Host Business Update Webcast on September 27, 2018 GlobeNewswire
Sep-13-18 04:01PM  SIGA Technologies to Ring the Nasdaq Opening Bell on Friday, September 14, 2018 GlobeNewswire
Sep-10-18 05:50PM  SIGA Technologies Awarded BARDA Contract for TPOXX® GlobeNewswire
Jul-16-18 10:42AM  Siga Continues Rally After FDA Approves Smallpox Drug Benzinga
Jul-13-18 03:47PM  U.S. Food and Drug Administration Approves SIGA Technologies TPOXX® (tecovirimat) for the Treatment of Smallpox GlobeNewswire +17.79%
03:33PM  SIGA Technologies shares rise 10% on approval of first-ever smallpox therapy MarketWatch
Jul-05-18 07:30AM  Pivotal Trial Data for SIGA Technologies Oral TPOXX® Published in the New England Journal of Medicine GlobeNewswire
May-31-18 07:30AM  SIGA to Present at the Jefferies Global Healthcare Conference on June 8, 2018 GlobeNewswire
May-03-18 08:31AM  Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss Benzinga
May-02-18 07:41AM  Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings Benzinga +10.36%
May-01-18 04:03PM  SIGA Technologies Announces Favorable Outcome of Advisory Committee In Support of TPOXX® GlobeNewswire
07:05AM  SIGA Technologies Stock Trading Halted Today; FDA Advisory Committee is Scheduled to Review New Drug Application of TPOXX® GlobeNewswire
Feb-27-18 08:30AM  Emerging Developments: New Research on Siga Technologies and Tropicana Entertainment - A Look Ahead into 2018 ACCESSWIRE
Aug-25-17 10:58AM  SIGA Technologies, Inc. :SIGA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York, New York.